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Abstract 30 
Several recent reports have described associations between gestational diabetes 31 
(GDM) and changes to the epigenomic landscape where the DNA samples were 32 
derived from either cord or placental sources. We employed genome-wide 450k 33 
BeadChip-Array analysis to determine changes to the epigenome in a unique cohort 34 
of maternal blood DNA from 11 pregnant women prior to GDM development relative to 35 
matched controls. Hierarchical clustering segregated the samples into two distinct 36 
clusters comprising GDM and healthy pregnancies. Screening identified 100 CpGs 37 
with a mean β-value difference of ≥0.2 between cases and controls. Using stringent 38 
criteria, 5 CpGs (within COPS8, PIK3R5, HAAO, CCDC124 and C5orf34 genes), 39 
demonstrated potentials to be clinical biomarkers as revealed by differential 40 
methylation in 8 of 11 women who developed GDM relative to matched controls. We 41 
identified, for the first time, maternal methylation changes prior to the onset of GDM 42 
that may prove useful as biomarkers for early therapeutic intervention. 43 
 44 
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Introduction 48 
Gestational diabetes (GDM) is a pregnancy-specific endocrine disorder with a 49 
prevalence of 3.5-14%.1 Due to the worldwide obesity epidemic and recently modified 50 
diagnostic criteria, GDM is increasingly prevalent.2 It occurs because of a mismatch 51 
between insulin production and requirement, leading to maternal hyperglycaemia. 52 
Since glucose is able to cross the placenta, whilst insulin does not, the fetus is also 53 
exposed to hyperglycaemic conditions. Women with GDM are at increased risk of 54 
Caesarean section and stillbirth compared with healthy women.3, 4 They are also more 55 
likely to develop type 2 diabetes (T2DM), dyslipidemia and cardiovascular disease in 56 
later life,5-7 while their offspring have an increased long-term risk of obesity and 57 
diabetes.2 58 
 59 
Epigenetic modifications, which may be causal of or associated with changes in gene 60 
expression, offer significant promise for understanding the underlying mechanisms of 61 
GDM. Indeed, and as an example, epigenetic changes in T2DM have been reported 62 
in genes involved in metabolism.8-13 Since maternal epigenetic modifications are 63 
known to contribute to fetal programming,14 recent studies have investigated the role 64 
of epigenetic alterations in offspring exposed to maternal hyperglycaemia and found 65 
positive associations.15-19 Furthermore, previous studies suggest that epigenetic 66 
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modifications may play a role in the pathogenesis of GDM.20, 21 67 
 68 
Epigenetic research in GDM has largely used targeted (candidate gene) 69 
approaches.15, 16, 18, 19 To date, only two studies have utilised genome-wide 70 
methodology17, 22 and in these cases investigators examined placenta and cord blood 71 
samples from GDM pregnancies. Differentially methylated genes were identified 72 
between GDM and healthy pregnancies,17, 22 which provide evidence for the 73 
involvement of these genes and/or their differential methylation in GDM. However, 74 
there have been no genome-wide studies examining methylation differences between 75 
maternal tissue samples from GDM and healthy pregnancies. We decided to focus on 76 
maternal epigenetic profiles, as they would facilitate the assessment of the in utero 77 
environment and allow identification of predictive biomarkers that would enable 78 
targeted intervention to high risk groups. 79 
 80 
On the basis of the current literature, we hypothesised the presence of pre-existing 81 
epigenetic markers in women who subsequently go on to develop GDM. In this study, 82 
and for the first time in this disease, we interrogated genome-wide DNA methylation in 83 
peripheral blood samples collected from women prior to the development of GDM and 84 
relative to matched healthy controls that did not develop GDM. Using this discovery 85 
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cohort, our aim was to identify candidate genes with future promise as potential 86 
biomarkers for the prediction of GDM in early pregnancy. 87 
 88 
Results 89 
Our initial data analyses focused on comparison of our data in antenatal samples with 90 
the two recent genome-wide studies that investigated cord blood and placental tissue 91 
samples.17, 22 We compared our data with those of Finer et al.22 and Ruchat et al.17 92 
separately due to the different approaches used for data processing by each study 93 
(Figure 1). Using the filtering criteria shown in step 1A of Figure 1, comparison of our 94 
data with those of Finer et al.22 identified 4,755 differentially methylated CpGs 95 
(representing 2,236 genes) where the mean β-value difference between the GDM and 96 
healthy groups was >0.05 and statistically significant (p<0.05). In contrast, 97 
comparison with the data of Ruchat et al.17 (step 1B of Figure 1) identified 1,035 98 
CpGs (representing 633 candidate genes). We also performed the same comparison 99 
after applying multiple testing adjustment using the false discovery rates, which 100 
showed no overlap of our data with these two studies.  101 
 102 
As shown in Figure 2A, by comparing the 2,236 genes identified as differentially 103 
methylated in our study with those reported by Finer et al.,22 two genes were common 104 
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between maternal blood, umbilical cord and placenta: Hook Microtubule-Tethering 105 
Protein 2 (HOOK2) and Retinol Dehydrogenase 12 (RDH12). Conversely, and as 106 
summarised by the Venn diagram in Figure 2B, there were no genes common to all 107 
three tissue types when we compared our data with that of Ruchat et al.17  108 
 109 
The 4,755 CpGs initially identified as differentially methylated were then subjected to 110 
further filtering (steps 2 and 3, Figure 1). Using this approach, we identified 100 111 
unique CpGs (comprising 66 genes) that were differentially methylated between GDM 112 
and healthy pregnancies (the full annotated list is shown in Table S1). None of these 113 
CpGs have an annotated single-nucleotide polymorphism (SNP) in the probe. Closer 114 
examination of the 100 CpGs revealed that the majority (53%) were hypomethylated 115 
in GDM relative to healthy pregnancies. The observed differences in mean β-value 116 
showed a maximum difference of 0.38. The frequency and DNA methylation of these 117 
differentially methylated CpG sites in relation to their genomic location and CpG 118 
islands are shown in Figure S1. Of the differentially methylated CpGs, 45% were 119 
associated with a CpG island, shelf or shore (Figure S1C). 120 
 121 
Hierarchical clustering was performed to determine whether the methylation patterns 122 
in these 100 CpGs can be used to distinguish between GDM and healthy pregnancies. 123 
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The heatmap in Figure 3 illustrates that there are distinctive methylation patterns 124 
between GDM and healthy pregnancies, which segregate samples into two distinct 125 
groups comprising those from GDM and healthy populations. The slide type did not 126 
cause the clustering, therefore our results were not due to batch effects. Calculation of 127 
the genomic inflation factor before and after normalisation steps showed that removal 128 
of SNP containing probes and subset-quantile within array normalisation (SWAN) 129 
normalisation by the minfi package reduced the genomic inflation.23-25 130 
Pre-normalisation λ was estimated to be 1.189 (standard error of the estimation = 131 
9.461 x 10-5) and after normalisation the estimated lambda was reduced to 1.132 132 
(standard error of the estimation = 7.461 x 10-5). The remaining genomic inflation 133 
suggests that mild confounding stratification factors remain unaccounted for in the 134 
data.  135 
 136 
Enrichment of gene ontology terms and biological pathways within the 66 genes 137 
associated with differentially methylated CpGs were assessed using DAVID online 138 
software26 identified 11 overrepresented pathways, with the top three (ranked by p 139 
value) involved in cell adhesion molecules, type 1 diabetes mellitus and keratin 140 
pathways. However, enrichment of these pathways was not statistically significant 141 
following adjustment for false discovery rates (Table S2). 142 
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 143 
Finally, we examined the absolute β-value differences across all 11 matched pairs. 144 
Using this stringent criteria, in 5 of the 100 CpGs identified, at least 8 of the 11 GDM 145 
pregnancies showed β-value differences of >0.2 relative to matched controls. The 5 146 
CpGs comprised of 5 genes (COPS8, PIK3R5, HAAO, C5orf34 and CCDC124) and 147 
their functions are shown in Table 1. 148 
 149 
Discussion 150 
We describe for the first time, genome-wide DNA methylation changes in maternal 151 
blood prior to the diagnosis of GDM. We identified 2 differentially methylated genes 152 
that shared identity with genes previously described in studies which interrogated 153 
placenta and umbilical cord blood samples and, in these cases, using the same array 154 
platforms.17, 22 Furthermore, using stringent filtering criteria, we identified 100 unique 155 
CpGs which segregated GDM and healthy pregnancies into distinct groups upon 156 
hierarchical clustering.  157 
 158 
The strength of our study, in contrast to the previous studies, is that we carefully 159 
matched each GDM pregnancy to a healthy one to ensure the samples were 160 
comparable.17, 22 Furthermore, as all samples were taken prior to development of 161 
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pregnancy complications, there was limited sampling bias. 162 
 163 
We were able to compare our data to those from two recent genome-wide studies in 164 
GDM using cord blood and placenta tissue.17, 22 Comparative analysis with Finer et 165 
al.22 showed that HOOK2 and RDH12 were common to maternal blood, placenta and 166 
cord blood. HOOK2 codes for a linker protein which mediates binding to organelles 167 
and is responsible for morphogenesis of cilia and endocytosis.27, 28,29 RDH12 encodes 168 
a retinal reductase, which also plays a role in the metabolism of short-chain 169 
aldehydes.27, 30 In terms of KEGG orthology, it is involved in metabolic pathways as 170 
well as retinal metabolism.31 These two genes, therefore, may represent important 171 
candidates for further study.   172 
 173 
The disparity of candidate genes when comparisons are made to the previous studies 174 
might reflect the different data filtering criteria used by Ruchat et al. 17 and Finer et 175 
al.22 Using the Finer et al. criteria, many of the differentially methylated CpGs are 176 
likely to have β-value differences of <0.2, which could be difficult to reproduce either 177 
by alternative methodologies such as Pyrosequencing or in replication studies using 178 
independent patient cohorts. Moreover, we used a distinct patient population to the 179 
other two studies. We used samples from women prior to the development of their 180 
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GDM, while both Ruchat et al.17 and Finer et al.22 used samples from women with 181 
established GDM. Furthermore, we used maternal blood samples, rather than 182 
placenta and cord blood samples. These disparities may have contributed to the 183 
differences in the absolute numbers of CpGs/genes identified. 184 
 185 
Further analysis of our cohort identified 100 independent CpGs (comprising 66 genes), 186 
which were found to cluster GDM and healthy pregnancies separately. Reassuringly, 187 
these CpGs have no annotated SNPs in the probe. Enrichment of gene ontology 188 
terms and biological pathways of these 66 genes showed enrichment for genes 189 
involved in cell adhesion, type 1 diabetes mellitus and keratin pathways.26, 32 Although 190 
the enrichment was not statistically significant following adjustment for false discovery 191 
rates, these are promising candidates which are worth examining to elucidate the 192 
biological mechanisms behind GDM. In future work, it will be important to verify, in 193 
larger independent cohorts, the candidates identified herein and to determine the 194 
impact of differential methylation. This may in the future improve the understanding of 195 
GDM pathogenesis and aid in the development of therapy. 196 
 197 
The design of this pilot study was to generate a list of genes of interest using a 198 
relatively small number of samples. In order to avoid type II errors (false negatives), 199 
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we used uncorrected p values to identify potential candidates in the preliminary 200 
screening. We then applied more stringent methodology (steps 2-4 of Figure 1) to 201 
identify candidate genes. A potential limitation of our study is the possibility of 202 
genomic inflation. Mild confounding stratification factors, such as changes in 203 
composition of blood during the pregnancy, the time of blood sampling, and parity, 204 
may have inflated the data. Therefore, we further validated the array data using an 205 
independent method with Pyrosequencing in order to confirm our findings. 206 
 207 
On closer inspection, 8 of 11 women who subsequently developed GDM showed 208 
differential methylation at 5 CpGs (consisting of COPS8, PIK3R5, HAAO, CCDC124 209 
and C5orf34 genes) relative to matched controls. COPS8 encodes a regulator of 210 
multiple signaling pathways.27, 33 It is involved in protein binding and negative 211 
regulation of cell proliferation.33, 34 The PIK3R5 protein has important roles in cell 212 
growth, proliferation, motility, differentiation, survival, and intracellular trafficking.27, 213 
35-37 The HAAO protein catalyses the synthesis of quinolinic acid (QUIN). Increased 214 
cerebral levels of QUIN may participate in the pathogenesis of neurologic and 215 
inflammatory disorders, which may be mediated by HAAO.27, 38 This unique epigenetic 216 
signature may form the basis of future biomarker studies using a larger validation 217 
cohort. The CCDC124 protein is involved in cell cycle and division.39 C5orf34 encodes 218 
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for a protein which is highly conserved across species, however its function remains 219 
uncharacterised.27  220 
 221 
In summary, for the first time using a genome-wide approach in maternal blood, we 222 
have identified maternal methylation changes prior to the diagnosis of GDM. As a 223 
discovery-based study, our findings may prove useful towards developing simple 224 
biomarkers for predicting GDM, thus facilitating intervention strategies in the early 225 
antenatal period to improve the health of the mother and baby, both during pregnancy 226 
and in the long-term. 227 
 228 
Materials and Methods 229 
Patients 230 
Peripheral blood samples were obtained from women prospectively recruited at the 231 
University Hospital of North Midlands, UK, between 12-16 weeks gestation, prior to 232 
the diagnosis of any pregnancy complications as part of the EFFECT-M study.40 At the 233 
end of pregnancy, we identified 11 women who had GDM and individually matched 234 
each one with a healthy woman who had a normal pregnancy. They were matched in 235 
terms of age, body mass index, ethnicity, smoking status, medications and folate 236 
supplementation (Table S3). The study was approved by the West Midlands (Black 237 
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Country) Research Ethics Committee (REC reference no. 08/H1204/121). 238 
 239 
Genome-wide DNA methylation profiling 240 
We performed genome-wide analysis of DNA methylation using the Illumina 241 
HumanMethylation450 BeadChip-Array which examines over 480,000 individual CpG 242 
sites. We first extracted genomic DNA from blood samples collected into potassium 243 
EDTA using standard phenol/chloroform procedures. Next, samples were sodium 244 
bisulfite converted 41 and hybridised to arrays according to Illumina recommended 245 
protocols that we have previously described.42 Methylation at individual CpGs is 246 
reported as a methylation β-value, which is a quantitative measure of methylation for 247 
each CpG site with range between 0 (no methylation) to 1 (completely methylated).  248 
 249 
Validation by sodium bisulfite pyrosequencing 250 
A technical validation between array β-values and methylation levels was determined 251 
by sodium bisulfite pyrosequencing in all 22 samples. To increase template quantity 252 
for Pyrosequencing assays, whole genome amplification of bisulfite-converted DNA 253 
followed by touchdown PCR were performed as previously described.42 A PyroMark 254 
Q24 instrument was used to run Pryosequencing assays according to the 255 
manufacturer’s instructions (Qiagen). Analyses of Pyrograms were conducted on the 256 
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PyroMark Q24 software (v 2.0.6., build 20; Qiagen). Seven CpGs representing 5 257 
genes were chosen to provide a range of β-values. These demonstrated a strong 258 
positive correlation between β-values and percentage methylation by bisulphite 259 
sequencing (Spearman’s r = 0.92, Figure S2). 260 
 261 
Data analysis 262 
Each array passed quality control assessment based on the performance of internal 263 
array controls. Initial processing, probe type correction and assessment of array data 264 
was conducted using the minfi package and SWAN.23, 24 Probes with known SNPs 265 
were removed. All CpGs for which one or more of the 22 samples displayed detection 266 
p values > 0.05 (indicating an unreliable site) or presented with missing β-values were 267 
excluded. The genomic inflation factor (λ, the ratio of the median of the observed 268 
distribution of the test statistic to the expected median) was calculated using the 269 
estlambda function of GenABEL.25 270 
 271 
We filtered the data using criteria shown in Figure 1 to identify differentially 272 
methylated sites between GDM and healthy pregnancies. In step the first analysis, we 273 
elected to use a minimum β-value difference of 0.05, in part to permit comparisons 274 
with a recent report describing DNA methylation in placenta and umbilical cord blood 275 
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from GDM pregnancies also using the 450k array platform (step 1, Figure 1).22 The 276 
genes identified as differentially methylated were obtained from the supplementary 277 
data of this particular publication. We also compared our data with a separate cohort 278 
of placenta and umbilical cord blood samples from GDM pregnancies.17 We obtained 279 
their list of differentially methylated genes through personal communication with the 280 
corresponding author of the publication. Further filtering steps were applied to 281 
facilitate a more stringent analysis. To reduce the number of non-variable sites to 282 
improve the statistical power of subsequent analyses, we removed all sites with 283 
β-values ≥0.8 and ≤0.2 in all 22 samples (step 2, Figure 1). This is an approach that 284 
has been used by our group and as well as others.41-44 As described previously by our 285 
group, we consider it a more robust methodology to remove from the data set CpGs 286 
that failed in any one of the samples, instead of eliminating specific failed CpGs from 287 
specific samples.42 We retained only those CpGs which had a mean β-value 288 
difference of ≥0.2 (step 3, Figure 1). Finally we examined the absolute β-values in 289 
each matched pairs. We used a cut-off of ≥0.2 mean β-values difference to identify 290 
CpGs with considerable methylation differences. 291 
 292 
Hierarchical clustering was performed utilising Genesis software (v1.7.6) using 293 
Euclidian distance and average linkage criteria.45 Enrichment of gene ontology terms 294 
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and biological pathways within the genes associated with differentially methylated 295 
CpGs were assessed using DAVID online software. 26, 32 296 
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Table 1. Annotation for the 5 genes differentially methylated in 8 of 11 matched pairs, 439 
as determined by genome-wide DNA methylation analysis. *The official gene symbol, 440 
gene name and stated function were retrieved from the NCBI Gene database 441 
(accessed September 2015). **The absolute β-value difference range is the minimum 442 
to the maximum value of the individual absolute β-value differences for each 443 
differentially methylated CpG. 444 
Gene 
symbol* 
Absolute β-value 
difference 
range** 
Gene name* Functional 
summary 
COPS8 0.05-0.84 
 
Constitutive 
photomorphogenic 
homolog subunit 8 
Regulator of multiple 
signaling pathways 
PIK3R5 0.02-0.82 
 
Phosphoinositide-3-kinase, 
regulatory subunit 5 
Cell growth, 
proliferation, 
differentiation, 
motility, survival, and 
intracellular 
trafficking 
HAAO 0.02-0.77 
 
3-hydroxyanthranilate 
3,4-dioxygenase 
Catalyses the 
synthesis of 
quinolinic acid 
(QUIN), which is 
an excitotoxin that 
may participate in the 
pathogenesis of 
neurologic and 
inflammatory 
disorders 
CCDC124 0.01-0.79 
 
Coiled-coil domain 
containing 124 
Cell cycle, cell 
division 
C5orf34 0.01-0.77 
 
Chromosome 5 open 
reading frame 34 
Unknown, but 
sequence is 
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 conserved in 
chimpanzee, Rhesus 
monkey, dog, cow, 
mouse, rat, chicken, 
and zebrafish 
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Supplementary Table S1. Full annotated list of 100 differentially methylated CpGs. 445 
CpG UCSC_Refgene_Name UCSC_Refgene_Group UCSC_CPG_Islands_Name Relation_to_UCSC_CpG_Island 
cg03206401 TUBA3E TSS200 chr2:130955619-130956274 Island 
cg16322792 ZNF697 3'UTR chr1:120165302-120166626 Island 
cg17155524 ZFYVE28 Body chr4:2305514-2305793 Island 
cg21358336 
  
chr17:6558221-6558441 Island 
cg24686902 
  
chr17:6558221-6558441 Island 
cg24863815 NFIC Body chr19:3398628-3398935 Island 
cg00684178 NEU4 5'UTR;1stExon chr2:242754323-242754629 Shelf 
cg02877261 
  
chr4:186064047-186064614 Shelf 
cg06684911 ATP8B3 Body chr19:1795922-1797001 Shelf 
cg08436396 LYPD5 TSS1500;5'UTR chr19:44302665-44303176 Shelf 
cg09101062 C5orf34 Body chr5:43483519-43484555 Shelf 
cg11331837 
  
chr17:35165323-35165983 Shelf 
cg12515659 FAM134B Body chr5:16616509-16617428 Shelf 
cg13033971 
  
chr13:46287282-46288214 Shelf 
cg16569309 
  
chr19:36266234-36266622 Shelf 
cg17830140 POLRMT Body chr19:615691-623505 Shelf 
cg18391209 CAPN8 Body chr1:223741965-223744525 Shelf 
cg18678716 
  
chr5:195087-195323 Shelf 
cg20976286 OCA2 Body chr15:28050250-28050789 Shelf 
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CpG UCSC_Refgene_Name UCSC_Refgene_Group UCSC_CPG_Islands_Name Relation_to_UCSC_CpG_Island 
cg21211688 ADAMTSL2 Body chr9:136399367-136400274 Shelf 
cg21927991 ZFAT Body chr8:135490786-135491086 Shelf 
cg22274196   chr13:95953337-95954211 Shelf 
cg24976563 DCAF11 Body chr14:24583268-24584243 Shelf 
cg25174111 MUS81 Body chr11:65624495-65628596 Shelf 
cg26864826   chr11:33757476-33758122 Shelf 
cg01225004   chr14:101923575-101925995 Shore 
cg02823329 PIK3R5 Body chr17:8791470-8792004 Shore 
cg03292225 TNNT3 Body chr11:1958934-1959247 Shore 
cg04131969 MYADML Body chr2:33952422-33952684 Shore 
cg05237503 FBXO3 TSS1500 chr11:33795392-33796319 Shore 
cg05305893 FGF11;CHRNB1 3'UTR;TSS1500 chr17:7348274-7348830 Shore 
cg05918715 SHISA2 Body chr13:26624725-26626265 Shore 
cg06012903 PTPRN2 Body chr7:157980786-157981462 Shore 
cg06223162 GPR88 TSS200 chr1:101004471-101005885 Shore 
cg07878625 ZNF783 Body chr7:148978762-148979390 Shore 
cg08332163 AIM1L TSS200 chr1:26672445-26672650 Shore 
cg08693140   chr7:6654745-6655860 Shore 
cg09084244 CDK2AP1 TSS1500 chr12:123755246-123756408 Shore 
cg09086151 HLA-DRB1 Body chr6:32551851-32552331 Shore 
cg14114910 MORN5 Body chr9:124921950-124922170 Shore 
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CpG UCSC_Refgene_Name UCSC_Refgene_Group UCSC_CPG_Islands_Name Relation_to_UCSC_CpG_Island 
cg15441831 CLDN4 TSS200 chr7:73245434-73246045 Shore 
cg16995742 COPS8 TSS1500 chr2:237994004-237994876 Shore 
cg18624102 FBXO27 TSS1500 chr19:39522264-39523227 Shore 
cg21838924 CLDN4 TSS200 chr7:73245434-73246045 Shore 
cg22996768 
  
chr19:33717512-33717930 Shore 
cg01105403 
    
cg01153376 MIR662;MSLN 3'UTR;TSS1500 
  
cg01835922 
    
cg01872988 DKFZp686A1627 TSS1500 
  
cg01979298 
    
cg02113055 
    
cg02389264 
    
cg02909570 
    
cg03129555 
    
cg03706056 SETD4 TSS1500 
  
cg04028540 
    
cg04497820 
    
cg05138546 KRT36 TSS200 
  
cg05515244 CDH5 5'UTR 
  
cg05531409 CPNE4 5'UTR 
  
cg05809586 KRTAP27-1 1stExon 
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CpG UCSC_Refgene_Name UCSC_Refgene_Group UCSC_CPG_Islands_Name Relation_to_UCSC_CpG_Island 
cg06002687     
cg06281714    
 
cg06407043    
 
cg06979386     
cg07240846 CAMK1D Body   
cg07576186 PDHB 3'UTR   
cg08084984 XYLT1 Body 
  
cg08669168 SCFD2 Body 
  
cg08963013 LRRTM4 Body 
  
cg09284209 
    
cg10058204 FLJ37201 Body 
  
cg10701801 OSBPL9 TSS200 
  
cg10858640 SDK1 Body 
  
cg11047442 
    
cg11786587 
    
cg11957130 ATXN7L1 Body;5'UTR 
  
cg12342501 
    
cg12469381 CHN2 TSS200;Body 
  
cg13160852 LOC399959 Body 
  
cg13469425 TEC Body 
  
cg14007688 DBH Body 
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CpG UCSC_Refgene_Name UCSC_Refgene_Group UCSC_CPG_Islands_Name Relation_to_UCSC_CpG_Island 
cg14044669 C6orf10 Body   
cg14060113 CCDC124 3'UTR 
  
cg17174466 SPATS2L Body 
  
cg17283620 HAAO Body 
  
cg17738613 GPC5 Body   
cg17839758 C21orf29;KRTAP12-3 Body;TSS1500 
  
cg18584561 GREB1 TSS1500;5'UTR 
  
cg19248407 CUX1 Body 
  
cg19393008 KRT82 Body 
  
cg22274273 
    
cg22304519 
    
cg22436195 
    
cg24136292 INSC Body 
  
cg24470466 HLA-DQA1 Body 
  
cg24534774 
    
cg25550823 
    
cg25673075 
    
cg27079096 OR52B4 TSS200 
  
 446 
  447 
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Supplementary Table S2. Pathway analysis using DAVID. The gene ontology pathways and functional category terms, which were 448 
overrepresented by the 66 genes identified by differential methylation (difference in β-values >0.2) between GDM and control cases, are ordered 449 
by their p value. FDR= false discovery rate. 450 
Category Term p Value Fold Enrichment FDR 
KEGG_PATHWAY hsa04514:Cell adhesion molecules (CAMs) 0.006 9.63 6.05 
KEGG_PATHWAY hsa04940:Type I diabetes mellitus 0.007 22.70 6.38 
SP_PIR_KEYWORDS Keratin 0.011 8.62 11.93 
UP_SEQ_FEATURE Sequence variant 0.016 1.23 18.80 
GOTERM_BP_FAT GO:0009405~Pathogenesis 0.016 118.67 20.37 
SP_PIR_KEYWORDS Polymorphism 0.018 1.24 19.00 
GOTERM_CC_FAT GO:0005882~intermediate filament 0.022 6.50 22.28 
GOTERM_CC_FAT GO:0045111~intermediate filament cytoskeleton 0.023 6.36 23.41 
GOTERM_MF_FAT GO:0030280~structural constituent of epidermis 0.028 68.33 29.11 
SP_PIR_KEYWORDS Alternative splicing 0.039 1.33 37.35 
KEGG_PATHWAY hsa04670: Leukocyte transendothelial migration 0.046 8.08 37.75 
 451 
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Supplementary Table S3. (A) Clinical characteristics of GDM and healthy pregnancy samples. (B) Summary data of the study population. C, 452 
control. G, GDM. BMI, body mass index. IVF, in vitro fertilisation. SD, standard deviation. 453 
(A) 454 
Sample 
ID 
Age BMI Parity Ethnicity 
Smoking 
Status 
Medication 
Folic 
acid 
G1 20 35 0 White British Ex-smoker None Yes 
C1 39 33 0 White British Ex-smoker None Yes 
G2 32 20 
0 
White British Non-smoker 
IVF medication prior to 
pregnancy 
Yes 
C2 22 20 1 White British Non-smoker None Yes 
G3 22 36 1 White British Non-smoker None Yes 
C3 29 38 1 White British Non-smoker Orlistat prior to pregnancy Yes 
G4 33 37 1 White British Smoker None Yes 
C4 25 34 1 White British Smoker None Yes 
G5 26 30 1 White British Non-smoker Amoxicillin prior to pregnancy Yes 
C5 26 30 0 White British Non-smoker None Yes 
G6 35 25 1 Asian or Asian British-Indian Non-smoker Thyroxine Yes 
C6 33 28 0 Asian or Asian British-Pakistani Non-smoker None Yes 
G7 38 27 0 White British Non-smoker None Yes 
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C7 33 27 1 White British Non-smoker None Yes 
G8 40 35 3 White British Non-smoker Thyroxine Yes 
C8 31 34 2 White British Non-smoker Medication for hay fever Yes 
G9 32 39 0 Western Europe Non-smoker None Yes 
C9 30 44 1 White British Non-smoker None Yes 
G10 35 27 1 Asian or Asian-British Indian Non-smoker Antibiotics Yes 
C10 33 31 4 Asian or Asian British-Indian Non-smoker Antibiotics Yes 
G11 36 24 1 White British Non-smoker Medication for vertigo Yes 
C11 35 26 2 White British Non-smoker None Yes 
 455 
(B) 456 
Clinical Characteristics GDM (n = 11) Healthy (n = 11) 
Age (year, mean ± SD) 31.7 ± 6.4 30.6 ± 4.8 
BMI (median, interquartile range) 30 (25-36) 31 (27-34) 
Parity (median, interquartile range) 1 (0-1) 1 (0-2) 
 457 
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Legends 458 
Figure 1. Filtering criteria for the identification of CpGs differentially methylated 459 
between GDM and normal pregnancies. The starting number of CpGs (484,273) was 460 
derived through the removal of CpGs with high detection values (p >0.05) and those 461 
with missing β-values in any one of the 22 samples, as described in the Materials and 462 
Methods. Horizontal line denotes additional filtering steps. *According to Finer et al. 463 
criteria.22 **According to Ruchat et al. criteria.17 GDM, gestational diabetes. SD, 464 
standard deviation. 465 
 466 
Figure 2. Venn diagrams illustrating comparison of genes differentially methylated in 467 
GDM using maternal blood with those identified in cord blood and placenta of GDM 468 
affected pregnancies from the cohorts of (A) Finer et al.22 and (B) Ruchat et al.17, 469 
respectively. The genes from our dataset that were common with the other study are 470 
shown in dark gray shading. Genes identified as differentially methylated in Finer et 471 
al.22 were obtained from Supplementary file 2 of the published article, while the list of 472 
differentially methylated genes identified by Ruchat et al.17 was kindly provided 473 
through personal communication with the corresponding author of Ruchat et al.17 474 
 475 
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Figure 3. Heatmap and dendrograms showing clustering45 for the 100 CpGs 476 
identified as differentially methylated (mean difference in β-values >0.2) between 477 
GDM and healthy pregnancies. DNA methylation across the 100 sites in each of the 478 
samples was analysed by hierarchical clustering using the Euclidean distance and 479 
average linkage criteria. Each row represents an individual CpG site and each 480 
column a different sample. Healthy controls and GDM samples are shown by the 481 
green and red bars, respectively. Slide type is also shown with slide 1 in green and 482 
slide 2 in red. Color gradation from yellow to blue represents low to high DNA 483 
methylation respectively, with β-values ranging from 0 (no methylation; yellow) to 1 484 
(complete methylation; blue). GDM, gestational diabetes. 485 
 486 
Supplementary Figure S1. Characteristics of the 100 CpGs identified as differentially 487 
methylated using genome-wide 450k arrays. (A) Frequency of CpG sites according to 488 
their genomic location. (B) DNA methylation in GDM versus control samples plotted 489 
by genomic location. The llumina HumanMethylation450 BeadChip-Array annotations 490 
are used as the basis for gene regions. Data are presented as mean ± standard 491 
deviation. (C) Frequency of CpG sites according to their relationship with CpG islands. 492 
(D) DNA methylation in GDM versus control samples plotted by relationship with CpG 493 
islands. TSS proximal promoter defined as 200 bp (TSS200) or 1,500 bp (TSS1500) 494 
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upstream of the transcription start site. UTR, untranslated region. GDM, gestational 495 
diabetes. 496 
 497 
Supplementary Figure S2. Technical validation of 450k BeadChip-Array data by 498 
sodium bisulfite Pyrosequencing. Correlation of DNA methylation as measured by 499 
array β-value and by bisulfite Pyrosequencing for 166 individual sites in the 500 
participants. Spearman’s r = 0.92. (7 CpGs from 5 separate genes were selected to 501 
cover across the range of β-values: AHRR: cg23576855, IGF2: cg27331871, Mir886: 502 
cg26896946, cg26328633, PM20D1: cg07167872, cg24503407, TCF7L2: 503 
cg00159523). 504 
